Arthneeti

Strides Pharma Science Q2 FY27 Share Price & Earnings Call Analysis

₹1,097.50+1.10% today
Market cap
₹10,120 Cr
P/E
17.47
ROE
19.99%
PEG
0.24
Price to sales
2.02
Debt to equity
0.57
52W high / low
₹1,235 / ₹794
Sales growth (5Y)
7.94%
EBITDA margin
18.68%
Net profit margin
12.03%
Promoter holding
29.00%
Sales (last year)
₹5,004 Cr

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]

Guidance scorecard · Q2 FY27 call

What Strides Pharma Science Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

Revenue10–20%MarginsFlatCapexNone plannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • Strides aims to grow its U.S. business from USD 285 million to USD 375 million by FY28, driven by five levers including OTC business, controlled substances, new product launches, specialty channels, and new partnerships.
  • Controlled substances are expected to contribute significantly to growth following completion of past sales history demonstration (1.5 years demonstrated), with higher quota allocations anticipated from next cycles.
  • Approximately 10 product launches are planned by March next year, focusing on higher-revenue potential products (USD 10-15 million each).
  • Beyond FY28, growth is expected to be driven by advancements in three key domains—nasal sprays, transdermal patches, and thin films—with multiple filings and launches planned over next 12-18 months.

2 more points from Strides Pharma Science Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Strides Pharma Science Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

None planned
  • Current capex is a combination of maintenance capex, R&D, and hard capex, totaling about INR 2.5 to 3 billion per year.
  • No greenfield capex is planned at this point; focus remains on enhancing existing factories and investing in high-impact line items.
  • Strategic investment includes the sale of majority stake in Pivot Path, with retained 20% interest, expected to contribute to PAT in the next 4-5 years.
  • The company continues investments in new technology platforms like nasal sprays, transdermal patches, films, and controlled substances to support future growth.

2 more points from Strides Pharma Science Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Strides Pharma Science Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • The company highlighted delays in product approvals impacting near-term launches but expects growth in the U.S. from new approvals and launches in H2 FY27.
  • Controlled substances quota allocations, occurring bi-annually, have taken longer but are expected to improve in upcoming cycles, driving growth.
  • There is mention of supply chain logistics causing some temporary fulfillment issues in ex-U.S. markets, which the company aims to recover in subsequent quarters.

2 more points from Strides Pharma Science Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Strides Pharma Science Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Strides Pharma Science Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Strides Pharma Science Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Strides Pharma Science Ltd

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +27.39%25.88%25.86%25.84%26.82%28.30%28.30%27.86%27.86%27.91%27.91%29.00%
FIIs +19.45%24.57%26.71%30.08%28.48%28.32%28.02%28.51%29.52%28.68%28.40%27.98%
DIIs +19.02%17.66%18.17%18.24%16.92%13.72%13.30%12.98%13.02%14.44%15.42%15.51%
Government +0.39%0.39%0.39%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public +33.75%31.52%28.87%25.83%27.78%29.65%30.38%30.62%29.59%28.96%28.28%27.52%
No. of Shareholders91,18284,69591,91796,0091,14,23695,12592,88991,20685,58986,61694,85093,336

Financials of Strides Pharma Science Ltd

Quarterly Results

Quarter-by-quarter operating performance

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales +9309991,0061,0441,0541,1671,1541,1901,1201,2211,1951,3231,265
Expenses +7968898768748669839439739029909591,0841,037
Operating Profit134111129169188184210218218231236240228
OPM %14%11%13%16%18%16%18%18%19%19%20%18%18%
Other Income +3-12960-273,299254-12018104368
Interest76797071737452504746434241
Depreciation60604948474848494950515356
Profit before tax0-15770233,36986114106122153245148200
Tax %3,025%-5%23%55%1%16%21%20%13%14%15%13%17%
Net Profit +-9-14954103,350729086106132208129165
EPS in Rs-0.79-14.545.401.98364.697.819.548.9110.8013.8421.9313.7717.02

Financials of Strides Pharma Science Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +1,1962,8612,7552,8452,1782,7523,3163,0703,6883,8904,5654,8595,004
Expenses +9672,4862,2282,4481,9822,3382,7793,2013,5443,3623,7633,9334,070
Operating Profit229374527398197414537-131145528803925935
OPM %19%13%19%14%9%15%16%-4.3%3.9%14%18%19%19%
Other Income +87463291643303-43109-11292-1003,313124193
Interest4716818319679156150177261280249179172
Depreciation64131126154117174206233243214192202210
Profit before tax99213750969030342289-653-268-653,675669746
Tax %15%31%12%1%-9%27%11%-27%-21%45%2%14%
Net Profit +8449544668433031258-474-212-943,598575634
EPS in Rs141.7812.1544.7174.2536.274.0629.93-51.25-22.44-7.68389.7560.3466.56
Dividend Payout %76%41%10%3%8%345%8%0%-7%-33%1%8%

Financials of Strides Pharma Science Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital608989909090909090929292
Reserves1,0852,5692,6592,3742,5592,4382,6872,2692,1222,0342,4603,015
Borrowings +8923,5423,7002,5203,2212,2352,3483,0253,0302,5171,8801,758
Other Liabilities +4381,2111,5981,6011,9371,3691,8441,5561,3521,1571,4981,941
Total Liabilities2,4757,4108,0466,5857,8076,1316,9696,9406,5945,7995,9296,807
Fixed Assets +7012,6792,9802,9773,6482,0992,2192,3472,3111,8651,8992,101
CWIP171815780620453413447291151162207447
Investments6301,3411,525588702549697540490303409291
Other Assets +9722,5762,7622,4003,0053,0703,6053,7623,6423,4703,4143,967
Total Assets2,4757,4108,0466,5857,8076,1316,9696,9406,5945,7995,9296,807

Financials of Strides Pharma Science Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +837328818760205481-25844701684703
Cash from Investing Activity +50-2,205-1,222570-1451,321-522-119302-150-90-173
Cash from Financing Activity +-4212,944338-1,016194-1,709-16421-214-693-643-453
Net Cash Flow-288812-596-259110-184-5645133-142-4876
Free Cash Flow-157-293-386-212-25658188-326-43672505291
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit61%40%66%61%59%60%60%199%-30%128%77%84%

Financials of Strides Pharma Science Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1191321321131651241221441291079697
Inventory Days135149209146294254329285257235236305
Days Payable153188221188299259323260220178190244
Cash Conversion Cycle1029212071160119128168165164141157
Working Capital Days-916-122-4-70-70-22-28-11-192438
ROCE %57%8%11%16%2%5%8%-5%-0%7%15%18%

Guidance history

How Strides Pharma Science Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatNone planned——
Q4 FY26 call →10–20%FlatPlanned——
Q3 FY26 call →10–20%FlatPlanned——
Q2 FY26 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

69out of 100

Momentum score · price trend

69 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+29.0%77%
Last 6 months+5.9%62%
Last 3 months+2.3%68%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Strides Pharma Science Ltd: 0.4 × 77 + 0.4 × 62 + 0.2 × 68 = 69.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Strides Pharma Science Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

  • Aarti Pharmalabs Ltd (Q2 FY27)

    19,211.62 lakhs (~45.9% increase) . Key investor presentation takeaways from Aarti Pharmalabs Ltd's Q2 FY27 investor presentation — and how it ranks against sec

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd